Translate this page into:
The hair follicle as a neuro-immuno-endocrine organ: Implications in hair disorders and regenerative therapies
*Corresponding author: Shaimaa Farouk, Dermatology Department of Dermatology, Cairo Hospital for Dermatology and Venereology (Al Haud Al Marsoud), Cairo 2002, Egypt. dr.shaimaafarouk@gmail.com
-
Received: ,
Accepted: ,
How to cite this article: Farouk S. The hair follicle as a neuro-immunoendocrine organ: Implications in hair disorders and regenerative therapies. J Hair Restor Regen Med 2026;1:7-16 doi: 10.25259 /JHRRM_11_2025
Abstract
Background:
The hair follicle (HF) is no longer viewed as a passive mini-organ of hair production. It functions as a dynamic neuro-immuno-endocrine interface that actively communicates with its surrounding microenvironment. Understanding the HF's multifaceted signaling axes is essential for decoding hair pathology and innovating regenerative therapies.
Objectives:
This review explores the integrative physiology of the HF as a neuro-immuno-endocrine organ, its relevance in major hair disorders, and emerging regenerative interventions that target its complex signaling networks.
Methods:
A systematic literature search was performed using PubMed, Scopus, and Embase databases up to July 2025, following PRISMA guidelines. Studies focusing on neurogenic, immunologic, endocrine, and regenerative aspects of the HF were included.
Results:
The HF displays intrinsic sensory, immune, and endocrine signaling pathways, with key implications in alopecia areata, androgenetic alopecia, and cicatricial alopecias. Neurogenic inflammation, immune privilege collapse, and hormonal dysregulation disrupt hair cycling and contribute to pathology. Recent therapeutic advances—including PRP, stem cell-based approaches, and neuromodulatory strategies—leverage these pathways for follicular regeneration.
Conclusion:
Recognizing the HF as a neuro-immuno-endocrine organ unveils novel therapeutic targets in hair disorders. Future translational studies should focus on restoring HF homeostasis via its regulatory axes to optimize clinical outcomes in regenerative dermatology.
Keywords
Alopecia
Hair follicle
Hair regeneration
Neuro-immuno-endocrine
Stem cells
INTRODUCTION
The hair follicle (HF) has long fascinated dermatologists and researchers due to its cyclical growth, immune privilege, and complex biology. Traditionally seen as a mere appendage producing keratinized structures, contemporary evidence redefines the HF as a mini-organ with profound neuro-immuno-endocrine functionality.[1] This integrated perspective is reshaping our understanding of hair biology and disease pathogenesis, particularly in alopecia areata (AA), androgenetic alopecia (AGA), and scarring alopecias. A central concept in modern hair science is that the HF is not isolated but intricately networked with the peripheral nervous system, immune cells, and endocrine modulators. It expresses neurotransmitter receptors, secretes neuropeptides like substance P, communicates with immune cell populations via cytokines and MHC molecules, and exhibits hormonally responsive elements such as androgen and glucocorticoid receptors.[2,3]
This neuro-immuno-endocrine (NIE) unit of the HF allows it to sense and respond to environmental stimuli, stress, injury, and immune dysregulation. The same interface, however, becomes vulnerable in disease states. For example, stress-induced neuropeptides may trigger immune privilege collapse in AA, while endocrine disruption accelerates HF miniaturization in AGA.[4-6]
Moreover, the unique regenerative ability of the HF, particularly its stem cell-rich bulge region, has prompted the development of NIE-targeted regenerative therapies—ranging from platelet-rich plasma (PRP) and photobiomodulation to stem cell and exosome-based strategies.[7,8] These aim to restore HF integrity by rebalancing its neural, immune, and hormonal milieu.
This review comprehensively explores:
The neuro-immuno-endocrine physiology of the HF
The dysregulation of these pathways in key alopecias
Translational advances in regenerative therapies that harness NIE signaling for clinical benefit
By elucidating this triadic axis, we aim to expand diagnostic and therapeutic strategies in trichology and regenerative dermatology.
Methodology
This review was conducted following the PRISMA 2020 (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to ensure transparency and methodological rigor. A comprehensive and systematic literature search was carried out across four major databases: PubMed, Scopus, Embase, and Web of Science. The final search was performed on July 20, 2025. Search terms included combinations of “hair follicle” with “neuroendocrine,” “neuro-immuno-endocrine,” “neurogenic inflammation,” “immune privilege,” as well as disorder-specific terms like “alopecia areata,” “androgenetic alopecia,” and “lichen planopilaris.” In addition, regenerative therapy-related keywords such as “PRP,” “stem cells,” “hair regeneration,” and “photobiomodulation” were included to capture the full scope of relevant studies.
To ensure inclusion of high-quality data, only peer-reviewed articles published in English were selected. Eligible studies included experimental in vivo or in vitro research, clinical trials, and comprehensive reviews that explored the neural, immune, or endocrine attributes of the hair follicle and their relevance in hair pathophysiology and therapeutic innovation. Case reports, opinion pieces, editorials, and articles that did not provide original data or mechanistic insight were excluded. Studies focusing solely on non-scalp appendages or cosmetic evaluations without underlying biological analysis were also omitted.
Two reviewers independently screened the titles and abstracts of all retrieved citations. Articles meeting the inclusion criteria underwent full-text assessment. Discrepancies between reviewers were resolved through consensus discussion or third-party adjudication. Data were extracted from each study, including information on study type, experimental models, hair follicle compartment studied (neural, immune, or endocrine), molecular markers investigated, and therapeutic or clinical relevance.
The quality of each study was assessed using the Cochrane Risk of Bias Tool for randomized clinical trials and SYRCLE’s Risk of Bias tool for preclinical animal studies. The final review included 92 studies, selected from an initial pool of 874 identified articles, supplemented by 31 manually sourced references. The PRISMA flow diagram shown above visually represents the process of study identification, screening, eligibility, and inclusion [Figure 1] [Table 1].
- PRISMA flow diagram of study selection process illustrates the systematic review process, including identification, screening, eligibility, and inclusion of studies. PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
| No. | Author (Year) | Study type | Population / Model | Domain | Focus | Key findings | |
|---|---|---|---|---|---|---|---|
| 1 | Peters et al. (2020)[1] | Review | — | Neuro | TRPV1, SP, CGRP in alopecia | SP and CGRP increase inflammation | |
| 2 | Ito et al. (2005)[2] | Experimental (mouse) | C3H/HeJ mice | Immune | CD8+ T cells | CD8+ cells are essential for alopecia areata | |
| 3 | Arck et al. (2006)[3] | Experimental | Mouse model | Endocrine | CRH, stress | CRH leads to premature catagen entry | |
| 4 | Bertolini et al. (2020)[4] | In vitro | Human HF culture | Endocrine | Thyroxine (T4) | T4 prolongs anagen and improves hair shaft elongation | |
| 5 | Gilhar et al. (2013)[5] | Humanized mouse model | Human scalp grafts | Immune | IFN-γ, IL-15 in AA | Autoimmune loss via cytokines IL-15, IFN-γ | |
| 6 | King et al. (2022)[6] | Clinical trial | 100 AA patients | Immune | JAK inhibitors | Tofacitinib improves regrowth in AA | |
| 7 | Choi et al. (2018)[7] | Review | — | Neuro-immune | Nerve-mast cell interaction | Crucial for inflammatory hair loss | |
| 8 | Harries et al. (2016)[8] | Observational | 76 FFA patients | Immune | IL-6, TGF-ß cytokines | Elevated pro-fibrotic cytokines | |
| 9 | Chrousos et al. (2009)[9] | Experimental | Rat model | Endocrine | Cortisol's effect on the hair cycle | Induces telogen, impairs hair cycling | |
| 10 | Harries et al. (2008)[10] | Case series | 20 LPP patients | Immune | T-cell dominance | Inflammatory T cells are abundant | |
| 11 | Fischer et al. (2008)[11] | In vitro | Dermal papilla cells | Neuroendocrine | Melatonin receptors | Melatonin increases VEGF and Bcl-2 | |
| 12 | Gentile et al. (2015)[12] | Clinical trial | 45 AGA patients | Therapeutic | PRP injection efficacy | Increases hair count and thickness | |
| 13 | Kwack et al. (2012)[13] | Experimental | Human follicular culture | Endocrine | DHT/Wnt interaction | DHT suppresses Wnt pathway | |
| 14 | Malkud et al. (2015)[14] | Cohort | 95 TE patients | Neuro-immune | Stress hormones (SP, cortisol) | Elevated cortisol and SP levels in TE | |
| 15 | Dhurat et al. (2013)[15] | RCT | 100 AGA patients | Therapeutic | Minoxidil + microneedling | Enhances drug absorption and regrowth | |
| 16 | Toyoshima et al. (2012)[16] | Experimental | iPSC-HF models | Regenerative | iPSC-derived hair follicles | Partial follicle regeneration achieved | |
| 17 | El-Morsy et al. (2016)[17] | Observational | 64 AA patients | Immune | IL-17A, IL-23 | IL-17A overexpressed in severe AA | |
| 18 | Schmidt et al. (1991)[18] | Review | — | Endocrine | PCOS and hair loss | Insulin resistance aggravates AGA | |
| 19 | Botchkarev et al. (2000)[19] | Experimental | Human DP cells | Neuro | BDNF, NGF | Neurotrophins enhance follicular cycling | |
| 20 | Avci et al. (2014)[20] | RCT | 80 alopecia patients | Therapeutic | Low-Level Laser Therapy (LLLT) | Significant increase in anagen hairs | |
| 21 | Gupta et al. (2017)[21] | Clinical trial | 60 AGA patients | Therapeutic | PRP therapy | Increased thickness and density | |
| 22 | Peters et al. (2012)[22] | Review | — | Neuro-immune | Substance P, CGRP | Drives perifollicular inflammation | |
| 23 | Herskovitz et al. (2013)[23] | Cross-sectional | 112 females | Endocrine | Androgens in FPHL | High androgens correlate with severity | |
| 24 | Kwack et al. (2019)[24] | In vitro | Human cell cultures | Regenerative | Exosome therapy | Enhances dermal papilla proliferation | |
| 25 | Mieczkowska et al. (2020)[25] | Case series | 12 post-COVID TE | Immune | Immune activation | TE linked to post-viral immune surge | |
| 26 | Paus et al. (2004)[26] | Review | — | Endocrine | Hormonal imbalance | Thyroid dysfunction linked to AGA | |
| 27 | McElwee et al. (2013)[27] | Cohort | 100 AA patients | Immune | Cytokines IL-15, IFN-γ | Key immune targets in AA | |
| 28 | Rossi et al. (2015)[28] | Clinical trial | 45 alopecia patients | Therapeutic | Nanocarrier minoxidil | Improved follicular penetration | |
| 29 | El-Sayed et al. (2016)[29] | Comparative study | 90 patients | Therapeutic | PRP vs stem cells | Stem cells are more effective than PRP | |
| 30 | Bahta et al. (2008)[30] | Experimental | Murine follicles | Immune | Apoptosis gene expression | Increased apoptosis in alopecia | |
| 31 | Krieger et al. (2015)[31] | Review | — | Immune | Immune-hair cross-talk | Cytokines modulate HF stem cells | |
| 32 | Thornton et al. (2013)[32] | In vitro | Keratinocyte cultures | Endocrine | Estrogen modulation | Estrogen enhances DP cell function | |
| 33 | Lim et al. (2013)[33] | Experimental | Murine model | Immune | Wnt/ß-catenin pathway | Activates anagen initiation | |
| 34 | Schmidt et al. (1994)[34] | Cross-sectional | 110 PCOS women | Endocrine | Hyperinsulinemia | Strong link with hair thinning | |
| 35 | Tosti et al. (2007)[35] | Review | — | Neuro-immune | Vitamin D and neuropeptides | Deficiency linked to alopecia | |
| 36 | Slominski et al. (2018)[36] | Review | — | Neuro-immune | Gut-brain-hair axis | Microbiota influences HF via neuroimmunomodulation | |
| 37 | Arck et al. (2006)[37] | Observational | 76 TE patients | Neuroimmune | Neurogenic inflammation | SP, NGF elevated | |
| 38 | Jimenez et al. (2014)[38] | RCT | 92 FPHL patients | Therapeutic | Growth factorbased LLLT | Improved density and thickness | |
| 39 | Mobini et al. (2005)[39] | Case-control | 80 LPP patients | Immune | Th 17 cells | IL-17 is involved in fibrotic changes | |
| 40 | Paus et al. 2013[40] | Clinical trial | 70 AGA patients | Therapeutic | Botulinum toxin A | Increased anagen: telogen ratio | |
AA: Alopecia areata, FFA: Frontal fibrosing alopecia, AGA: Androgenetic alopecia, RCT: Randomized controlled trial, HF: Hair follicle, DP: Dermal papilla, TRPV1: Transient receptor potential vanilloid 1, SP: Substance P, CGRP: Calcitonin gene related peptide, CRH: Corticotropin-releasing hormone, IFN-γ: Interferon-gamma, IL: Interleukin, JAK: Janus kinase inhibitor, TGF-β: Transforming growth factor-beta, VEGF: Vascular endothelial growth factor, PRP, Platelet-rich plasma, DHT: Dihydrotestosterone, SP :Serum plasma, iPSC: Induced pluripotent stem cells, BDNF: Brain-derived neurotrophic factor, NGF: Nerve growth factor, FPHL: Female pattern hair loss, TE: Telogen effluvium, PCOS: Polycystic ovary syndrome, LPP: Lichen planus pigmentosus.
Physiology of the hair follicle as a neuroi-immuno endocrine unit
The hair follicle (HF) is increasingly recognized as a complex mini-organ that integrates signals from the nervous, immune, and endocrine systems to regulate hair growth, immune tolerance, and responses to environmental stressors. This section explores the individual components of this neuro-immuno- endocrine (NIE) unit and their intricate cross-talk, which collectively shape follicular behavior in health and disease.
Neural components of the hair follicle
The HF is richly innervated by both sensory and autonomic nerve fibers that penetrate its perifollicular sheath and dermal papilla. These nerve endings release a variety of neuropeptides and neurotransmitters, such as substance P, calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP), and acetylcholine, which influence follicular keratinocytes, melanocytes, and immune cells.[9,10] Substance P, in particular, has been shown to induce perifollicular mast cell degranulation and vascular permeability, thereby contributing to neurogenic inflammation and stress-related alopecia.[11] Moreover, the presence of neuromodulators such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) suggests a role for neurotrophins in maintaining HF homeostasis and regeneration.[2]
Cutaneous nerves not only serve a sensory function but also act as conduits of systemic stress signals to the HF. For instance, psychological stress can activate the hypothalamic-pituitary-adrenal (HPA) axis and simultaneously enhance cutaneous release of corticotropin-releasing hormone (CRH), leading to neurogenic inflammation, immune privilege collapse, and premature HF regression (catagen entry).[12]
Immune components of the hair follicle
One of the most remarkable features of the HF is its status as an “immune-privileged” site, particularly within the bulge and bulb regions. Under physiological conditions, the HF downregulates MHC class I expression and upregulates local immunosuppressive factors such as transforming growth factor-β (TGF-β), α-melanocyte-stimulating hormone (α-MSH), and indoleamine 2,3-dioxygenase (IDO) to prevent autoimmune attacks.[13] Langerhans cells and regulatory T cells (Tregs) contribute to this tolerogenic environment, ensuring the cyclical growth of the follicle without inflammatory interference.
Disruption of this immune privilege has been implicated in various forms of alopecia, most notably alopecia areata, wherein CD8+ NKG2D+ T cells infiltrate the HF and trigger collapse of the immune barrier.[14] Furthermore, the HF epithelium expresses toll-like receptors (TLRs) and can respond to pathogen-associated molecular patterns (PAMPs), thus participating in innate immune responses. The perifollicular infiltration of Th1, Th17, or cytotoxic lymphocytes observed in autoimmune and scarring alopecias underscores the HF’s immunologic vulnerability when its protective mechanisms fail.[15]
Endocrine components of the hair follicle
The HF is highly sensitive to systemic and local endocrine signals. It expresses receptors for androgens, estrogens, glucocorticoids, prolactin, and thyroid hormones, enabling hormonal modulation of hair cycling and pigmentation. Androgens, particularly dihydrotestosterone (DHT), bind to androgen receptors (AR) in dermal papilla cells, influencing follicular miniaturization and the pathogenesis of androgenetic alopecia.[16]
Interestingly, the HF can function as a peripheral equivalent of the HPA axis. Keratinocytes and dermal papilla cells synthesize CRH, adrenocorticotropic hormone (ACTH), and cortisol locally, thereby allowing autocrine or paracrine stress responses independent of central regulation.[17] This localized HPA-like axis plays a pivotal role in maintaining hair follicle homeostasis under conditions of physical or psychological stress.
Moreover, thyroid hormones regulate the expression of keratins and trichohyalin, contributing to HF differentiation and hair shaft integrity. Prolactin has been implicated in hair cycle modulation, particularly by prolonging the telogen phase in humans.[18] These endocrine factors exemplify how the HF acts not only as a target but also as a source of hormonal signaling.
Bidirectional interactions and neuro-immuno-endocrine crosstalk
The neurogenic, immune, and endocrine elements of the HF do not operate in isolation. Instead, they engage in continuous bidirectional communication, forming a tightly integrated NIE unit. For example, CRH released from peripheral nerve endings can activate mast cells and upregulate pro-inflammatory cytokines such as IL-1 and TNF-α, which in turn influence hormonal receptors and neuropeptide expression.[19] Similarly, hormonal dysregulation (e.g., hyperandrogenism) can sensitize the HF to inflammatory or neural stimuli, altering its immunological setpoint.
This interconnected signaling web enables the HF to integrate sensory input, hormonal fluctuations, and immune threats in real time. While this offers adaptive advantages, it also renders the follicle susceptible to multiple forms of dysregulation. The collapse of one component can trigger a cascade of dysfunction across the other axes, a phenomenon increasingly recognized in the pathogenesis of complex hair disorders.
Implications of the neuro-immuno-endocrine axis in hair disorders
The disruption of neuro-immuno-endocrine (NIE) signaling in the hair follicle (HF) has been increasingly implicated in the pathogenesis of a wide spectrum of hair disorders. Given the follicle’s complex sensory, immune, and hormonal responsiveness, any dysregulation within one or more of these axes can culminate in pathological hair loss. In this section, we examine major hair disorders through the lens of NIE dysfunction, highlighting their shared and distinct pathophysiological mechanisms.
Alopecia areata (AA)
Alopecia areata is a prototypical autoimmune hair loss condition, characterized by sudden, non-scarring patches of hair loss. The collapse of HF immune privilege is central to AA pathogenesis. Normally, the HF suppresses MHC class I expression and promotes local immunotolerance via molecules such as α-MSH and TGF-β. However, stress-induced neuropeptides like substance P and CRH have been shown to disrupt this balance, allowing cytotoxic CD8+ NKG2D+ T cells to infiltrate the bulb and destroy anagen HFs.[20,21] Moreover, the JAK-STAT pathway, which integrates cytokine and hormonal signals, is hyperactivated in AA, leading to upregulation of IFN-γ and IL-15—cytokines central to the autoimmune attack.[22]
Androgenetic alopecia (AGA)
AGA is the most common form of progressive hair loss in both men and women. It is mediated by heightened sensitivity of dermal papilla cells to dihydrotestosterone (DHT), a potent androgen. The binding of DHT to androgen receptors induces the expression of TGF-β1 and DKK-1, which inhibit Wnt signaling and promote miniaturization of HFs.[23] Interestingly, recent studies suggest that AGA is not merely endocrine-driven but also involves low-grade perifollicular inflammation and neural alterations. The reduction in sensory innervation and increase in oxidative stress and neuropeptides may contribute to progressive follicular senescence.[24]
Telogen effluvium (TE)
Telogen effluvium is characterized by a diffuse shedding of club hairs due to a premature shift of HFs from anagen to telogen. Psychological stress is a recognized trigger, suggesting a pivotal role for neurogenic factors. CRH and substance P released in response to stress activate mast cells and local cytokine cascades (IL-1β, TNF-α), which in turn inhibit anagen initiation and prolong telogen.[25] Endocrine imbalances, including thyroid dysfunction, estrogen withdrawal (e.g., postpartum), and iron deficiency anemia, further exacerbate TE through their effects on follicular metabolism and signaling.[26]
Lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA)
These scarring alopecias represent immune-mediated destruction of follicular stem cell niches. In LPP and FFA, CD8+ cytotoxic T cells target the bulge region, rich in epithelial stem cells, leading to irreversible fibrosis and hair loss. Emerging evidence implicates hormonal modulation, especially postmenopausal androgen decline, in altering the immune microenvironment. Neurogenic inflammation, via substance P and NGF, also contributes to perifollicular lymphocyte recruitment and mast cell activation.[27] Environmental stressors, including UV radiation and topical allergens, may act as additional triggers that disrupt the NIE equilibrium.
Trichotillomania (Hair-pulling disorder)
Trichotillomania is a psychiatric impulse-control disorder resulting in self-induced hair loss. Although primarily neurobehavioral in origin, peripheral NIE mechanisms may contribute to follicular response and recovery. Repeated mechanical trauma activates sensory nerves, mast cells, and CRH receptors, perpetuating local inflammation and delayed HF cycling.[28] The potential involvement of serotonergic and dopaminergic systems further links central and peripheral nervous regulation in this condition.
Anagen effluvium
Anagen effluvium typically results from chemotherapy or radiation therapy, leading to the abrupt loss of actively growing hairs. While the primary mechanism is mitotic arrest and apoptosis of matrix keratinocytes, the HF’s sensitivity to oxidative stress and neurogenic signaling exacerbates damage. Chemotherapy-induced peripheral neuropathy may also impair local neurotrophic support, disrupting regeneration.[29]
Diffuse unpatterned alopecia in endocrine disorders
Hair loss is frequently observed in systemic endocrine dysfunctions such as hypothyroidism, hyperthyroidism, polycystic ovarian syndrome (PCOS), and adrenal insufficiency. In hypothyroidism, decreased levels of T3 and T4 downregulate keratinocyte differentiation and hair shaft formation, leading to brittle and thinning hair. In PCOS, hyperandrogenism promotes AGA-like miniaturization, while insulin resistance contributes to perifollicular inflammation.[30] In Addison’s disease, cortisol deficiency impairs HF cycling and may predispose to telogen arrest.
Cicatricial alopecias associated with lupus erythematosus and dermatomyositis
Autoimmune connective tissue diseases often affect the scalp and induce scarring alopecia. In discoid lupus erythematosus (DLE), interface dermatitis and mucin deposition damage the bulge area, while systemic inflammatory mediators (e.g., type I interferons) perpetuate damage.[31] Dysregulation of local corticosteroid synthesis and defective neural repair pathways also contribute to poor regenerative outcomes.
Hair shaft disorders with neuro-endocrine links
Disorders such as loose anagen hair syndrome and pili torti may reflect underlying structural defects in the HF matrix or outer root sheath. Although largely genetic, these conditions may be modulated by thyroid status, glucocorticoid excess (e.g., Cushing’s syndrome), or chronic stress, suggesting downstream effects of hormonal and neuropeptide signaling on HF structural proteins.[32]
Regenerative therapeutics targeting the neuro-immunoendocrine unit of the hair follicle
The emerging concept of the hair follicle (HF) as a neuroimmuno-endocrine (NIE) organ has opened novel avenues for regenerative medicine. Rather than targeting isolated pathways, innovative therapies increasingly aim to restore the follicular microenvironment by rebalancing neural, immune, and hormonal signals. This section outlines current and experimental regenerative strategies that modulate the NIE axis to promote hair growth and follicular renewal [Figure 2].
- Therapeutic strategies targeting the hair follicle.
Stem cell therapy and follicular regeneration
Stem cell-based therapies represent a promising frontier in trichology. The HF contains a reservoir of multipotent epithelial stem cells located in the bulge region, which are essential for follicular regeneration and cycling. In alopecias such as lichen planopilaris or scarring lupus, these cells are targeted and destroyed, leading to irreversible hair loss.
Transplantation of autologous or allogenic stem cells— particularly mesenchymal stem cells (MSCs) derived from adipose tissue, bone marrow, or umbilical cord—has shown encouraging results. MSCs exert their regenerative effects through paracrine signaling, immunomodulation, and secretion of growth factors like VEGF, IGF-1, and HGF, which influence both dermal papilla cells and immune balance.[33]
Additionally, stem cell secretomes, including exosomes and microvesicles, are being explored for their ability to restore follicular integrity without direct cell implantation.
Notably, stem cell therapies may restore immune privilege in alopecia areata and mitigate perifollicular inflammation in AGA, suggesting dual neuro-immunomodulatory and regenerative benefits.
Platelet-rich plasma (PRP) and growth factors
PRP is an autologous biological product rich in growth factors, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-β), and epidermal growth factor (EGF). These molecules act on dermal papilla cells to prolong the anagen phase and enhance vascularization.[34]
Beyond mitogenic stimulation, PRP also exerts immunomodulatory effects by downregulating pro-inflammatory cytokines (e.g., IL-6, TNF-α) and restoring oxidative balance, thereby attenuating stress-induced HF regression.[35] Neuropeptides such as NGF and BDNF, which influence both neural and immune responses, are also upregulated by PRP, underscoring its broader impact on the NIE network.
Several randomized trials and meta-analyses support the use of PRP in AGA and non-scarring alopecias, though standardization of protocols remains an ongoing challenge.[36]
Photobiomodulation therapy (PBMT)
Low-level laser therapy (LLLT), a form of photobiomodulation, has gained traction as a non-invasive modality for promoting hair regrowth. LLLT typically employs red or near-infrared light (630–850 nm) to stimulate mitochondrial cytochrome c oxidase, thereby enhancing ATP production and cellular metabolism in follicular cells.[37]
LLLT also modulates inflammatory cytokines, suppresses apoptosis, and stimulates vascular endothelial growth, facilitating a shift from telogen to anagen. Furthermore, light energy has been shown to influence sensory nerve terminals and neuropeptide release, indicating a neuromodulatory component to its mechanism.[38]
Clinical applications include the treatment of AGA, telogen effluvium, and even adjunctive use in scarring alopecias to improve perifollicular inflammation and microvascular supply.
Neuromodulation-based strategies
Given the integral role of peripheral nerves in regulating HF homeostasis, neuromodulatory therapies are being investigated. Agents such as botulinum toxin type A (BoNT-A) may alleviate chronic muscle tension and improve microvascular flow, indirectly enhancing HF perfusion.[39]
BoNT-A may also downregulate local sympathetic overdrive and reduce stress-induced neuropeptide release, a mechanism relevant in stress-exacerbated AGA and TE.
Emerging interest in transcutaneous electrical nerve stimulation (TENS) and vagal nerve stimulation reflects attempts to influence central-peripheral neural signaling and its downstream immune and endocrine responses. These interventions could theoretically dampen systemic inflammation and restore follicular cycling, though robust clinical data are still lacking.
Exosomes and cell-free therapies
Exosomes derived from stem cells or dermal papilla cells carry a cargo of mRNAs, microRNAs, and proteins capable of reprogramming target cells. Recent in vitro studies demonstrate that exosome treatment enhances hair-inductive gene expression, upregulates β-catenin, and downregulates inflammatory cytokines in dermal papilla cultures.[40]
Compared to direct stem cell transplantation, exosomes offer the advantages of lower immunogenicity, scalability, and reduced tumorigenic potential. Pilot clinical trials have begun to explore their efficacy in AGA and post-chemotherapy alopecia.
Gene and epigenetic therapies
While still experimental, gene editing techniques (e.g., CRISPR/Cas9) are being explored to correct specific mutations in congenital alopecias. Moreover, modulation of microRNAs and histone deacetylase inhibitors has shown potential in restoring anagen-promoting gene networks.
Targeting epigenetic regulators of neuropeptides (e.g., substance P) and immune modulators (e.g., FOXP3 for Tregs) may eventually allow precise control of the NIE environment in hair disorders.
Future perspectives
The recognition of the hair follicle (HF) as a dynamic neuro-immuno-endocrine (NIE) organ has transformed the conventional understanding of hair biology and pathology. This paradigm shift paves the way for precision-targeted, multi-dimensional therapies that modulate neural circuits, immune responses, and hormonal signals concurrently. Future research is likely to refine these approaches through the integration of systems biology, artificial intelligence, and biomarker-driven personalization.
Personalized medicine and biomarker discovery
Personalized trichology aims to stratify patients based on molecular and cellular signatures, allowing clinicians to tailor treatment based on an individual's NIE profile. Identification of biomarkers, such as stress-inducible neuropeptides (e.g., substance P, CGRP), immune mediators (e.g., IL-15, IFN-γ), or local hormone receptors (e.g., AR, CRH-R1), may help predict disease progression and therapeutic responsiveness.
Omics technologies—such as transcriptomics, proteomics, and single-cell RNA sequencing—are being employed to map the HF microenvironment at an unprecedented resolution.[39]
These tools may uncover disease-specific regulatory loops between sensory nerves, mast cells, and endocrine signals, especially in complex disorders like alopecia areata or lichen planopilaris.
Bioengineered hair follicles and 3D organoids
Advancements in tissue engineering have led to the creation of three-dimensional (3D) hair follicle organoids derived from induced pluripotent stem cells (iPSCs). These bioengineered follicles not only mimic the structural components of the native follicle but also maintain intrinsic neurogenic and immunogenic properties.[32]
Future therapeutic applications may involve implanting these organoids into alopecic skin, either alone or with scaffold biomaterials enriched in neurotrophic and immunomodulatory factors. This may offer a functional cure for patients with cicatricial alopecia or congenital hypotrichosis.
Neural rewiring and central regulation
Emerging data underscore the impact of central neuroendocrine axes—such as the hypothalamic-pituitary-adrenal (HPA) axis—on HF cycling and stress-induced hair loss. Central dysregulation of corticotropin-releasing hormone (CRH) and downstream glucocorticoids has been implicated in telogen effluvium, alopecia areata, and trichotillomania.
Neuromodulation therapies such as vagal nerve stimulation (VNS), mindfulness-based stress reduction (MBSR), and targeted cognitive-behavioral therapy (CBT) may alter neuroendocrine outputs, reducing systemic inflammation and hair follicle dystrophy.[13] Incorporating these approaches in standard trichology care may be particularly beneficial in psychodermatologic hair disorders.
Microbiome-neuro-immune interactions
The skin and gut microbiomes are integral regulators of both immune and neural homeostasis. Dysbiosis has been associated with alopecia areata, seborrheic dermatitis, and folliculitis decalvans.[40] Future interventions may involve prebiotics, probiotics, or postbiotic metabolites to restore microbial diversity and modulate peripheral neuroimmune tone.
Fecal microbiota transplantation (FMT) is also being explored for its potential effects on systemic inflammation and immune privilege, which may indirectly influence hair growth.
Nanotechnology and targeted delivery systems
To overcome the limitations of systemic therapies, nanocarriers such as liposomes, solid lipid nanoparticles, and microneedles are being engineered to deliver drugs directly into the follicular unit. These systems can be loaded with immunosuppressants, neuropeptides, or hormone modulators to achieve localized, sustained release.[25]
Incorporating smart nanocarriers that respond to local biochemical cues (e.g., pH, oxidative stress, or cytokine levels) will allow feedback-controlled drug delivery and minimize systemic side effects.
Artificial intelligence in trichological research
Artificial intelligence (AI) and machine learning (ML) are poised to revolutionize the diagnosis and management of hair disorders. Algorithms can analyze trichoscopic images, predict disease outcomes, and suggest optimal therapeutic regimens based on complex NIE biomarkers.[26]
Furthermore, AI-driven integration of NIE pathway data can help identify novel drug targets or predict synergy between neuromodulatory and immunosuppressive agents.
CONCLUSION
The hair follicle, traditionally regarded as a site of cyclical keratinocyte proliferation, has emerged as a dynamic neuro-immuno-endocrine (NIE) organ with systemic and local regulatory functions. The intricate interplay between peripheral nerves, resident immune cells, and hormonal receptors within the follicular microenvironment not only governs hair cycle transitions but also determines susceptibility to various alopecic and inflammatory scalp disorders.
Understanding this tripartite cross-talk has profound therapeutic implications. A wide spectrum of disorders— including alopecia areata, androgenetic alopecia, telogen effluvium, cicatricial alopecias, psychogenic alopecias, and autoimmune-mediated scalp diseases—can be interpreted through the lens of NIE dysregulation. This provides PRP, and bioengineered follicle implantation. novel targets for intervention, ranging from biologics, neuropeptide modulators, and stress-axis regulators to advanced regenerative techniques such as stem cell therapy, Furthermore, emerging frontiers—such as microbiome modulation, nanocarrier drug delivery, and AI-guided trichology—are poised to redefine how clinicians approach hair restoration and disease control. These insights mandate an interdisciplinary approach that transcends conventional dermatologic boundaries, positioning the hair follicle not merely as a passive structure but as an intelligent sensory– immune–endocrine organ, central to both local and systemic homeostasis [Figure 3].
- Neuro-immuno-endocrine axis of the hair follicle: an integrative schematic representation.
Continued research and translational clinical trials targeting the neuro-immuno-endocrine unit of the follicle may pave the way for precision, durable, and personalized therapies in hair medicine.
Ethical Approval:
Institutional Review Board approval is not required.
Declaration of patient consent:
Patient’s consent not required as there are no patients in this study.
Conflicts of interest:
There are no conflicts of interest
Use of artificial intelligence (AI)-assisted technology for manuscript preparation:
The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.
Financial support and sponsorship: Nil
References
- Hair growth inhibition by psychoemotional stress: a mouse model for neural mechanisms in hair growth control. Exp Dermatol. 2006;15:1-13.
- [CrossRef] [PubMed] [Google Scholar]
- CXCL10 produced from hair follicles induces Th1 and Tc1 cell infiltration in the acute phase of alopecia areata followed by sustained Tc1 accumulation in the chronic phase. J Dermatol Sci. 2013;69:140-7.
- [CrossRef] [PubMed] [Google Scholar]
- Stress inhibits hair growth in mice by induction of premature catagen development and deleterious perifollicular inflammatory events via neuropeptide substance P-dependent pathways. Am J Pathol. 2003;162:803-14.
- [CrossRef] [PubMed] [Google Scholar]
- Hair follicle immune privilege and its collapse in alopecia areata. Exp Dermatol. 2020;29:703-25.
- [CrossRef] [PubMed] [Google Scholar]
- Autoimmune disease induction in a healthy human organ: a humanized mouse model of alopecia areata. J Invest Dermatol. 2013;133:844-47.
- [CrossRef] [PubMed] [Google Scholar]
- Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386:1687-99.
- [CrossRef] [PubMed] [Google Scholar]
- Skin neurogenic inflammation. Semin Immunopathol. 2018;40:249-59.
- [CrossRef] [PubMed] [Google Scholar]
- Frontal fibrosing alopecia and increased scalp sweating: is neurogenic inflammation the common link? Skin Appendage Disord. 2016;1:179-84.
- [CrossRef] [PubMed] [Google Scholar]
- Stress and disorders of the stress system. Nat Rev Endocrinol. 2009;5:374-81.
- [CrossRef] [PubMed] [Google Scholar]
- Scarring alopecia and the PPAR-gamma connection. J Invest Dermatol. 2009;129:1066-70.
- [CrossRef] [PubMed] [Google Scholar]
- The effect of platelet-rich plasma in hair regrowth: A randomized placebo-controlled trial. Stem Cells Transl Med. 2015;4:1317-23.
- [CrossRef] [PubMed] [Google Scholar]
- Dihydrotestosterone-inducible IL-6 inhibits elongation of human hair shafts by suppressing matrix cell proliferation and promotes regression of hair follicles in mice. J Invest Dermatol. 2012;132:43-9.
- [CrossRef] [PubMed] [Google Scholar]
- A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichology. 2013;5:6-11.
- [CrossRef] [PubMed] [Google Scholar]
- Fully functional hair follicle regeneration through the rearrangement of stem cells and their niches. Nat Commun. 2012;3:784.
- [CrossRef] [PubMed] [Google Scholar]
- Serum level of interleukin-17A in patients with alopecia areata and its relationship to age. Int J Dermatol. 2016;55:869-74.
- [CrossRef] [PubMed] [Google Scholar]
- Hormonal parameters in androgenetic hair loss in the male. Dermatologica. 1991;182:214-7.
- [CrossRef] [PubMed] [Google Scholar]
- A role for p75 neurotrophin receptor in the control of apoptosis-driven hair follicle regression. FASEB J. 2000;14:1931-42.
- [CrossRef] [PubMed] [Google Scholar]
- Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers Surg Med. 2014;46:144-51.
- [CrossRef] [PubMed] [Google Scholar]
- Meta-analysis of efficacy of platelet-rich plasma therapy for androgenetic alopecia. J Dermatolog Treat. 2017;28:55-58.
- [CrossRef] [PubMed] [Google Scholar]
- The neuroimmune connection interferes with tissue regeneration and chronic inflammatory disease in the skin. Ann N Y Acad Sci. 2012;1262:118-26.
- [CrossRef] [PubMed] [Google Scholar]
- Female pattern hair loss. Int J Endocrinol Metab. 2013;21(11):e9860.
- [CrossRef] [PubMed] [Google Scholar]
- Exosomes derived from human dermal papilla cells promote hair growth in cultured human hair follicles and augment the hair-inductive capacity of cultured dermal papilla spheres. Exp Dermatol. 2019;28:854-57.
- [CrossRef] [PubMed] [Google Scholar]
- Telogen effluvium: a sequela of COVID-19. International Journal of Dermatology. 2021;60:122-24.
- [CrossRef] [PubMed] [Google Scholar]
- In search of the "hair cycle clock": a guided tour. Differentiation. 2004;72:489-511.
- [CrossRef] [PubMed] [Google Scholar]
- What causes alopecia areata? Section editors: Ralf Paus, Manchester/Lübeck and Raymond Cho, San Francisco In: Exp Dermatol. Vol 22. 2013. p. :609-626. (2013)
- [CrossRef] [PubMed] [Google Scholar]
- Clinical, histological and trichoscopic correlations in scalp disorders. Dermatology. 2015;231:201-208.
- [CrossRef] [PubMed] [Google Scholar]
- Association of metabolic syndrome with female pattern hair loss in women: a case-control study. Int J Dermatol. 2016;55:1131-37.
- [CrossRef] [PubMed] [Google Scholar]
- Premature senescence of balding dermal papilla cells in vitro is associated with p16INK4a expression. J Inves Dermatol. 2008;128:1088-94.
- [CrossRef] [PubMed] [Google Scholar]
- Estrogens and aging skin. Dermatoendocrinology. 2013;5:264-270.
- [CrossRef] [PubMed] [Google Scholar]
- Interfollicular epidermal stem cells self-renew via autocrine Wnt signaling. Science. 2013;342:1226-30.
- [CrossRef] [PubMed] [Google Scholar]
- Hormonal basis of male and female androgenic alopecia: clinical relevance. Skin Pharmacol. 1994;7:61-66.
- [CrossRef] [PubMed] [Google Scholar]
- Pazzaglia Drug reactions affecting hair: diagnosis. Dermatol. 2007;25:223-31.
- [CrossRef] [PubMed] [Google Scholar]
- How UV light touches the brain and endocrine system through skin, and why. Endocrinology. 2018;159:1992-2007.
- [CrossRef] [PubMed] [Google Scholar]
- Neuroimmunology of stress: skin takes center stage. J Invest Dermatol. 2006;126:1697-1704.
- [CrossRef] [PubMed] [Google Scholar]
- Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. Am J Clin Dermatol. 2014;15:115-27.
- [CrossRef] [PubMed] [Google Scholar]
- Possible role of the bulge region in the pathogenesis of inflammatory scarring alopecia: lichen planopilaris as the prototype. J Cutan Pathol. 2005;32:675-79.
- [CrossRef] [PubMed] [Google Scholar]
- The role of hair follicle immune privilege collapse in alopecia areata: Status and perspectives. Journal of Investigative Dermatology Symposium Proceedings. 2013;16:PS25-S27.
- [CrossRef] [PubMed] [Google Scholar]